Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.09. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
04.08. | H.C. Wainwright bestätigt Kaufempfehlung für Medicenna mit Kursziel von 2,50 $ | - | Investing.com Deutsch | ||
04.08. | H.C. Wainwright reiterates Buy rating on Medicenna stock with $2.50 target | 1 | Investing.com | ||
04.08. | H.C. Wainwright reiterates Buy rating on Medicenna stock, maintains $2.50 target | 1 | Investing.com | ||
01.08. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
01.08. | Medicenna Therapeutics Corp. Q1 Loss Rises | 1 | RTTNews | ||
01.08. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 104 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen | |
31.07. | Stocks in Play: Medicenna Therapeutics Corp | - | Baystreet.ca | ||
MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
26.06. | Medicenna Therapeutics GAAP EPS of -C$0.15 | 3 | Seeking Alpha | ||
26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights | 296 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA®... ► Artikel lesen | |
01.05. | Medicenna Therapeutics Corp: Medicenna presents preclinical MDNA113 data at meeting | 1 | Stockwatch | ||
29.04. | Medicenna Therapeutics Corp: Medicenna's MDNA11 showing acceptable safety profile | 1 | Stockwatch | ||
29.04. | Medicenna Therapeutics has "elegant science", Research Capital says | 2 | Cantech Letter | ||
22.04. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
26.03. | Medicenna Therapeutics Corp: Medicenna to present MDNA11 update at AACR | 1 | Stockwatch | ||
26.03. | Stocks in Play: Medicenna Therapeutics Corp. | - | Baystreet.ca | ||
13.02. | Medicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones | 177 | GlobeNewswire (Europe) | - Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck's (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1... ► Artikel lesen | |
05.12.24 | Medicenna Therapeutics Corp.: Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study | 186 | GlobeNewswire (Europe) | 70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada)... ► Artikel lesen | |
15.11.24 | Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update | 225 | GlobeNewswire (Europe) | MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression... ► Artikel lesen | |
11.11.24 | Medicenna Therapeutics Corp.: Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA (pembrolizumab) at the ... | 188 | GlobeNewswire (Europe) | Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SUMMIT THERAPEUTICS | 18,940 | +1,83 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
BIONTECH | 82,50 | +0,06 % | OpenDoor, Almonty Industries, BioNTech - Große Chancen außerhalb der Tech-Blase | Während in der vergangenen Woche der Nasdaq 100 mit den führenden Technologiewerten weiter an Momentum verlor, konnte das Krisenmetall Gold bei 3.586 USD je Unze ein neues historisches Hoch feiern.... ► Artikel lesen | |
ARCELLX | 76,19 | -1,92 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ADMA BIOLOGICS | 16,110 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 38,885 | -0,29 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,710 | +8,94 % | Avidity Biosciences: BofA Securities erhöht Kursziel auf 65 US-Dollar | ||
EVOTEC | 5,818 | -0,34 % | Evotec Aktie: Und nun?- Aixtron, BioNTech, Hensoldt, Knaus Tabbert und Smartbroker im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
TOURMALINE BIO | 47,600 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 23,750 | +2,37 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
MAZE THERAPEUTICS | 23,270 | -6,17 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
TANGO THERAPEUTICS | 6,530 | -4,39 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 37,060 | -0,32 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
ENLIVEN THERAPEUTICS | 19,960 | +0,20 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 49,380 | -4,80 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
TREVI THERAPEUTICS | 8,250 | -15,38 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen |